Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMONK0F)

Drug Name
GNF-PF-2272 Drug Info
Synonyms
3-Methyltoxoflavin; GNF-Pf-2272; MLS000528498; SMR000121073; 1,3,6-Trimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione; BAS 00444306; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione; 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione; SR-01000322764; methyltoxoflavin; CPXHNWKHOFNPDO-UHFFFAOYSA-N; 3-methyl toxoflavin; AC1LA2XZ; 32502-62-8; cid_460747; SCHEMBL2180986; CHEMBL601757; BDBM34671; CHEBI:95315; KUC104460N; HMS2304H14; STK397047; KSC-1-228; MCULE-2510138695; NCGC00093522-02; NCGC00093522-01; HY-111117
Cross-matching ID
PubChem CID
460747
ChEBI ID
CHEMBL95315
TTD Drug ID
D0P0CM

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
IL-17 signaling pathway 2.12 0.00e+0 84/94 (89.36%) FOSB;FOS;CXCL8;...
TNF signaling pathway 2.05 0.00e+0 103/112 (91.96%) FOS;JUNB;TNFAIP3;...
Legionellosis 2.03 0.00e+0 51/57 (89.47%) CXCL8;HSPA6;HSPA1A;...
Pertussis 2.00 2.50e-3 64/76 (84.21%) FOS;CXCL8;IL6;...
MAPK signaling pathway 1.96 2.00e-3 272/294 (92.52%) GADD45B;FOS;DUSP5;...
Colorectal cancer 1.95 1.66e-3 84/86 (97.67%) GADD45B;FOS;GADD45A;...
Breast cancer 1.92 1.43e-3 119/147 (80.95%) GADD45B;FOS;GADD45A;...
Basal cell carcinoma 1.91 1.25e-3 41/63 (65.08%) GADD45B;GADD45A;CDKN1A;...
Rheumatoid arthritis 1.85 5.55e-3 78/93 (83.87%) FOS;CXCL8;IL6;...
NF-kappa B signaling pathway 1.81 9.99e-3 90/104 (86.54%) GADD45B;CXCL8;TNFAIP3;...
Fluid shear stress and atherosclerosis 1.79 1.73e-2 123/139 (88.49%) FOS;HMOX1;DUSP1;...
Malaria 1.78 1.91e-2 44/50 (88%) CXCL8;IL6;HBB;...
Graft-versus-host disease 1.77 2.38e-2 32/42 (76.19%) IL6;HLA-DQA1;TNF;...
Antigen processing and presentation 1.76 2.28e-2 60/78 (76.92%) HSPA6;HSPA1A;LGMN;...
FoxO signaling pathway 1.71 3.26e-2 118/131 (90.08%) GADD45B;PLK2;KLF2;...
Bladder cancer 1.71 3.31e-2 40/41 (97.56%) CXCL8;CDKN1A;HBEGF;...
AGE-RAGE signaling pathway in diabetic complications 1.70 3.70e-2 97/100 (97%) CXCL8;EGR1;IL6;...
Apoptosis 1.69 3.72e-2 126/168 (75%) GADD45B;FOS;GADD45A;...
Lipid and atherosclerosis 1.69 3.57e-2 190/215 (88.37%) FOS;CXCL8;HSPA6;...
Melanoma 1.68 3.50e-2 68/72 (94.44%) GADD45B;GADD45A;CDKN1A;...
PD-L1 expression and PD-1 checkpoint pathway in cancer 1.66 3.61e-2 79/89 (88.76%) FOS;JUN;TICAM1;...
Transcriptional misregulation in cancer 1.65 4.04e-2 158/192 (82.29%) GADD45B;CXCL8;GADD45A;...
Kaposi sarcoma-associated herpesvirus infection 1.64 4.30e-2 172/193 (89.12%) FOS;CXCL8;IL6;...
Gastric cancer 1.64 4.12e-2 122/149 (81.88%) GADD45B;GADD45A;CDKN1A;...
Toll-like receptor signaling pathway 1.63 4.67e-2 94/104 (90.38%) FOS;CXCL8;IL6;...
Leishmaniasis 1.62 4.84e-2 67/77 (87.01%) FOS;JUN;ITGA4;...
Apelin signaling pathway 1.60 4.96e-2 117/137 (85.4%) EGR1;KLF2;CCN2;...
Collecting duct acid secretion -1.77 3.01e-2 22/27 (81.48%) ATP6V1C1;ATP6V0D1;ATP4B;...
Phosphatidylinositol signaling system -1.79 3.51e-2 82/97 (84.54%) PI4KA;PIP5K1C;IP6K1;...
Vibrio cholerae infection -1.80 4.68e-2 44/50 (88%) ACTB;ATP6V1C1;ATP6V0D1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 20uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H